Skip to main content

Table 1 Patients’ baseline characteristic

From: Centrosome associated genes pattern for risk sub-stratification in multiple myeloma

 

Training cohorta

Validation cohorta

No. of patients

73

78

Follow-up median (min–max) [month]

23.6 (0.3–97.0)

18.6 (0.1–250.0)

Gender: males–females

49.3–50.7 %

55.1–44.9 %

Age median (range) [years]

69 (38–84)

66 (40–90)

ISS stage: I–II–III

28.8 %–27.3 %–43.9 %

24.7 %–35.1 %– 40.3 %

Durie-Salmon stage: I–II–III

4.3 %–14.3 %–81.4 %

3.8 %–29.5 %–66.7 %

Durie-Salmon substage: A–B

81.4 %–18.6 %

75.6 %–24.4 %

Ig isotype: IgG–IgA–FLC-Non-secr.

60.3 %–23.5 %–16.2 %

57.7 %–28.2 %–1.3 %–12.8 %

Light chains: kapp–lambda

58.0 %–42.0 %

53.8 %–46.2 %

Plasma cell infiltration in bone marrow

34.4 % (0.8 %–93.6 %)

36.0 % (2.2 %–81.2 %)

No. of previous treatment lines

 None (first line treatment)

57.7 % (41/71)

64.1 % (50/78)

 One

19.7 % (14/71)

15.4 % (12/78)

 Two

8.5 % (6/71)

10.3 % (8/78)

 More (>2)

14.1 % (10/71)

10.3 % (8/78)

Treatment regimen

 Bortezomib-based

47.8 % (32/67)

64.9 % (50/77)

 Thalidomide-based

14.9 % (10/67)

10.4 % (8/77)

 Lenalidomide-based

25.4 % (17/67)

18.2 % (14/77)

 Others

11.9 % (8/67)

6.5 % (5/77)

Treatment response

 CR-VGPR-PR-MR-SD-PG

12.3 %–29.8 %–22.8 %–5.3 %–5.3 %–26.3 %

10.8 %–20.0 %–27.7 %–7.7 %–4.6 %–29.2 %

Biochemical parameters

 Hemoglobin (g/l)

105.5 (67.0–151.0)

95.5 (65.9–146.0)

 Thrombocytes (×109)

192.0 (33.0–416.0)

188.5 (55.0–485.0)

 Calcium (mmol/l)

2.29 (1.74–23.37)

2.32 (1.75–2.78)

 Albumin (g/l)

38.2 (21.1–54.1)

35.7 (17.4–52.2)

 Creatinine (umol/l)

98.5 (53.0–783.0)

94.5 (30.0–849.0)

 β2-microglobulin (mg/l)

4.70 (1.79–42.60)

4.61 (1.62–50.0)

 Lactate dehydrogenase (ukat/l)

3.72 (1.53–22.92)

3.36 (1.14–7.77)

 C-reactive protein (mg/l)

3.6 (0.0–174.3)

4.0 (0.0–149.3)

 Monoclonal Ig (g/l)

29.8 (0.0–92.6)

30.2 (0.0–85.6)

Chromosomal abnormality

 Deletion 13q14

49.2 % (30/61)

60.0 % (39/65)

 Deletion 17p13

8.3 % (5/60)

13.8 % (9/65)

 Translocation t(4;14)

46.9 % (15/32)

44.4 % (16/36)

 Amplification 1q21

56.9 % (37/65)

54.5 % (36/66)

 Hyperdiploidy (H-MM)

45.5 % (30/66)

47.0 (17/46)

  1. CR complete response; VGPR very good partial response; PR partial response; MR minimal response; SD stable disease; PG progression
  2. aBoth cohorts have no significant difference in basic clinical parameters